tradingkey.logo
๎™๊ฒ€์ƒ‰
์‹œ์žฅ
๊ด€์‹ฌ ๋ชฉ๋ก
๋‰ด์Šค
๋ถ„์„
๋„๊ตฌ
์ข…๋ชฉ ์Šคํฌ๋ฆฌ๋„ˆ
๎™ผ
๎˜
English
็นไฝ“ไธญๆ–‡
เน„เธ—เธข
Tiแบฟng viแป‡t
็ฎ€ไฝ“ไธญๆ–‡
Espaรฑol
Portuguรชs
Deutsch
ํ•œ๊ตญ์–ด
๎˜ณ
ๆ—ฅๆœฌ่ชž
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™
๎˜

Acrivon Therapeutics Inc

ACRV
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
2.100USD
+0.040+1.94%
์‹œ์žฅ ์šด์˜ ์‹œ๊ฐ„ย 09/24, 12:46๏ผˆET๏ผ‰
89.88M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM

Acrivon Therapeutics Inc

2.100
+0.040+1.94%
๊ฐœ์š”
๋‰ด์Šค & ๋ถ„์„
๊ธˆ์œต
์ฃผ์‹ ์ ์ˆ˜
๊ธฐ์ˆ 
์˜ˆ์ƒ
์†Œ์œ ๊ถŒ
๋ฐฐ๋‹น๊ธˆ
ํ”„๋กœํ•„
ํ† ๋ก 
์žฌ๋ฌด ์š”์•ฝ์†์ต๊ณ„์‚ฐ์„œ์žฌ๋ฌด์ƒํƒœํ‘œํ˜„๊ธˆ ํ๋ฆ„ํ‘œ์žฌ๋ฌด์ œํ‘œ๊ธฐ์—… ๊ฐ€์น˜ ํ‰๊ฐ€์œ„ํ—˜ ์š”์†Œ

๊ฐœ์š”

๋‰ด์Šค & ๋ถ„์„

๊ธˆ์œต

์ฃผ์‹ ์ ์ˆ˜

๊ธฐ์ˆ 

์˜ˆ์ƒ

์†Œ์œ ๊ถŒ

๋ฐฐ๋‹น๊ธˆ

ํ”„๋กœํ•„

ํ† ๋ก 

์žฌ๋ฌด ์š”์•ฝ์†์ต๊ณ„์‚ฐ์„œ์žฌ๋ฌด์ƒํƒœํ‘œํ˜„๊ธˆ ํ๋ฆ„ํ‘œ์žฌ๋ฌด์ œํ‘œ๊ธฐ์—… ๊ฐ€์น˜ ํ‰๊ฐ€์œ„ํ—˜ ์š”์†Œ

ACRV ์žฌ๋ฌด ๋ฐ์ดํ„ฐ

์Šค๋งˆํŠธํ•œ ํˆฌ์ž์ž๋ฅผ ์œ„ํ•ด ์„ค๊ณ„๋œ ์˜ฌ์ธ์› ๋ฐ์ดํ„ฐ ๋Œ€์‹œ๋ณด๋“œ๋ฅผ ํ†ตํ•ด Acrivon Therapeutics Inc์˜ ์žฌ๋ฌด ๋ฐ์ดํ„ฐ๋ฅผ ํ™•์ธํ•˜์„ธ์š”. ๋ณต์žกํ•œ ์žฌ๋ฌด์ œํ‘œ๋ฅผ ์‚ฌ์šฉ์ž ์ •์˜ ๊ฐ€๋Šฅํ•œ ๋ทฐ๋กœ ๊ตฌ์„ฑํ•˜์—ฌ ์žฌ๋ฌด ๋ถ„์„์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. ์ตœ์‹  ์—ฐ๊ฐ„ ์žฌ๋ฌด ๋ณด๊ณ ์„œ์— ์ ‘๊ทผํ•˜๊ฑฐ๋‚˜, ์†์ต๊ณ„์‚ฐ์„œ, ์žฌ๋ฌด์ƒํƒœํ‘œ, ํ˜„๊ธˆ ํ๋ฆ„ํ‘œ๋ฅผ ์‚ฌ์šฉํ•˜์—ฌ ๋ถ„๊ธฐ๋ณ„ ์„ฑ๊ณผ๋ฅผ ๋ถ„์„ํ•˜์„ธ์š”. ์‹ค์‹œ๊ฐ„ ์žฌ๋ฌด ์ง€ํ‘œ๋ฅผ ์†๋์—์„œ ํ™•์ธํ•  ์ˆ˜ ์žˆ์–ด ํšŒ์‚ฌ์˜ ์‹œ์žฅ ๊ฑด์ „์„ฑ์„ ์‹œ๊ฐ„์— ๋”ฐ๋ผ ๊ทธ ์–ด๋Š ๋•Œ๋ณด๋‹ค ์‰ฝ๊ฒŒ ๋ชจ๋‹ˆํ„ฐ๋งํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

ํ•ต์‹ฌ ์žฌ๋ฌด ๋น„์œจ

์‹œ๊ฐ€์ด์•ก
89.88M
๋ฐฐ๋‹น ์ˆ˜์ต๋ฅ 
0.00
P/E TTM
-1.05
์ฃผ๋‹น์ˆœ์ด์ต
-2.00
์ˆ˜์ต
--
์ˆœ์ด์ต
-80.56M
ROE
-60.39%
ROA
-54.38%

Acrivon Therapeutics Inc ์‹ค์  ๋ฐœํ‘œ์ผ๎˜

์ตœ์‹  ์ถœ์‹œ
Aug 12, 2026
EPS / ์˜ˆ์ƒ
-0.43/-0.50
์ˆ˜์ต / ์˜ˆ์ƒ
--/0.00

์žฌ๋ฌด์ œํ‘œ ์š”์•ฝ

๋ถ„๊ธฐ๋ณ„๎˜ฎ
๋ถ„๊ธฐ๋ณ„+์—ฐ๊ฐ„
๋ถ„๊ธฐ๋ณ„
์—ฐ๊ฐ„
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
์žฌ๋ฌด ์ง€ํ‘œ
EPS
21.39%-0.43
4.18%-0.49
17.68%-0.49
19.71%-0.47
-4.98%-0.55
29.68%-0.51
30.79%-0.60
10.11%-0.59
17.85%-0.52
-25.41%-0.73
-111.58%-0.86
---0.66
---0.63
---0.58
---0.41
---1.07
----
์ˆœ์ด์ต
14.48%-17.96M
3.24%-19.04M
16.85%-18.98M
18.75%-18.23M
-11.75%-21.01M
-19.37%-19.68M
-18.59%-22.83M
-55.13%-22.44M
-35.10%-18.80M
-29.24%-16.49M
-115.61%-19.25M
-57.27%-14.47M
---13.91M
---12.76M
---8.93M
---9.20M
----
์†์ต๊ณ„์‚ฐ์„œ๎˜
์˜์—… ์ด์ต
17.58%-18.67M
8.12%-19.90M
19.39%-20.12M
21.69%-19.69M
-5.65%-22.65M
-22.61%-21.66M
-18.53%-24.95M
-55.79%-25.14M
-38.13%-21.44M
-22.75%-17.67M
-111.69%-21.05M
-68.53%-16.14M
---15.52M
---14.39M
---9.95M
---9.57M
----
์ˆœ์ด์ต
14.48%-17.96M
3.24%-19.04M
16.85%-18.98M
18.75%-18.23M
-11.75%-21.01M
-19.37%-19.68M
-18.59%-22.83M
-55.13%-22.44M
-35.10%-18.80M
-29.24%-16.49M
-115.61%-19.25M
-57.27%-14.47M
---13.91M
---12.76M
---8.93M
---9.20M
----
์žฌ๋ฌด์ƒํƒœํ‘œ๎˜
์œ ๋™์ž์‚ฐ
-33.90%91.49M
-34.43%99.22M
-33.69%120.44M
-31.02%130.36M
-24.10%138.41M
34.94%151.33M
40.05%181.63M
30.79%188.98M
18.97%182.36M
-9.54%112.14M
-1.82%129.69M
83.66%144.49M
75.86%153.28M
--123.96M
--132.09M
--78.67M
--87.16M
์œ ๋™ ๋ถ€์ฑ„ ์ด๊ณ„
-14.77%11.45M
-18.42%11.05M
-9.00%15.66M
0.49%14.89M
19.03%13.43M
49.87%13.55M
29.40%17.21M
59.36%14.82M
60.81%11.28M
59.12%9.04M
104.16%13.30M
45.50%9.30M
57.61%7.02M
--5.68M
--6.52M
--6.39M
--4.45M
์ด ์ž์‚ฐ
-37.51%99.09M
-38.85%107.83M
-34.02%129.72M
-32.32%145.30M
-31.23%158.58M
46.32%176.35M
42.18%196.59M
42.09%214.68M
44.07%230.59M
-29.19%120.52M
-23.71%138.26M
72.26%151.09M
68.48%160.05M
--170.20M
--181.23M
--87.71M
--95.00M
๋ถ€์ฑ„ ์ด๊ณ„
-20.06%12.43M
-22.82%12.32M
-13.14%17.20M
-6.16%16.70M
7.01%15.55M
27.24%15.96M
16.00%19.80M
37.46%17.79M
33.70%14.53M
28.93%12.54M
58.78%17.07M
19.72%12.94M
20.00%10.87M
--9.73M
--10.75M
--10.81M
--9.05M
์ž๋ณธ ์ด๊ณ„
-39.41%86.67M
-40.45%95.52M
-36.35%112.52M
-34.68%128.60M
-33.80%143.04M
48.54%160.39M
45.87%176.79M
42.52%196.89M
44.83%216.06M
-32.71%107.98M
-28.91%121.19M
79.64%138.15M
73.59%149.18M
--160.47M
--170.47M
--76.90M
--85.94M
ํ˜„๊ธˆ ํ๋ฆ„ํ‘œ๎˜
์ˆœ์˜์—…์ด์ต
10.52%-14.86M
-5.13%-20.54M
12.23%-15.24M
29.09%-12.28M
-19.47%-16.61M
-14.35%-19.54M
-40.38%-17.36M
-76.66%-17.32M
-52.58%-13.90M
-50.42%-17.08M
-32.20%-12.37M
-50.38%-9.81M
---9.11M
---11.36M
---9.35M
---6.52M
----
์ˆœํˆฌ์ž
-23.16%14.95M
-31.68%13.13M
49.35%21.52M
-63.08%5.91M
122.09%19.45M
228.44%19.21M
-29.82%14.41M
956.13%16.01M
-555.29%-88.04M
-37.28%5.85M
121.60%20.54M
103.36%1.52M
--19.34M
--9.33M
---95.07M
---45.12M
----
์ˆœ์žฌ๋ฌดํ™œ๋™
7593.81%7.27M
90.38%-33.00K
70.32%-192.00K
92.22%-117.00K
-100.08%-97.00K
-99.42%-343.00K
67.83%-647.00K
-2028.21%-1.50M
32446.17%123.35M
---172.00K
-101.97%-2.01M
155.71%78.00K
--379.00K
--0.00
--101.86M
---140.00K
----

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Acrivon Therapeutics Inc์˜ ์œ ๋™์ž์‚ฐ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Acrivon Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์œ ๋™์ž์‚ฐ์€ 120.44M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -33.69์ž…๋‹ˆ๋‹ค.

Acrivon Therapeutics Inc์˜ ์ด์ž์‚ฐ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Acrivon Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Acrivon Therapeutics Inc์˜ ์ด์ž์‚ฐ์€ 129.72M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -34.02์ž…๋‹ˆ๋‹ค.

Acrivon Therapeutics Inc์˜ ์ด๋ถ€์ฑ„๋Š” ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Acrivon Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Acrivon Therapeutics Inc์˜ ์ด๋ถ€์ฑ„๋Š” 17.20M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -13.14์ž…๋‹ˆ๋‹ค.

Acrivon Therapeutics Inc์˜ ์ด์ž๋ณธ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Acrivon Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Acrivon Therapeutics Inc์˜ ์ด์ž๋ณธ์€ 112.52M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -36.35์ž…๋‹ˆ๋‹ค.

Acrivon Therapeutics Inc์˜ ์ˆœ์˜์—…์†Œ๋“์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Acrivon Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Acrivon Therapeutics Inc์˜ ์ˆœ์˜์—…์†Œ๋“์€ -84.11M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 5.70์ž…๋‹ˆ๋‹ค.

Acrivon Therapeutics Inc์˜ ์ˆœํˆฌ์ž๋Š” ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Acrivon Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Acrivon Therapeutics Inc์˜ ์ˆœํˆฌ์ž๋Š” 66.10M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 227.68์ž…๋‹ˆ๋‹ค.

Acrivon Therapeutics Inc์˜ ์ˆœ์ž๊ธˆ์กฐ๋‹ฌ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Acrivon Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Acrivon Therapeutics Inc์˜ ์ˆœ์ž๊ธˆ์กฐ๋‹ฌ์€ -749.00K์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -100.62์ž…๋‹ˆ๋‹ค.

Acrivon Therapeutics Inc์˜ ์ฃผ๋‹น์ˆœ์ด์ต(EPS)์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Acrivon Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์ฃผ๋‹น์ˆœ์ด์ต(EPS)์€ -2.02์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 15.14์ž…๋‹ˆ๋‹ค.

Acrivon Therapeutics Inc์˜ ์ˆœ์ด์ต์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Acrivon Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์ˆœ์ด์ต์€ -77.91M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 3.29์ž…๋‹ˆ๋‹ค.

Acrivon Therapeutics Inc์˜ ์ž๊ธฐ์ž๋ณธ์ด์ต๋ฅ (ROE)์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Acrivon Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์ž๊ธฐ์ž๋ณธ์ด์ต๋ฅ (ROE)์€ -53.86์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 0.39์ž…๋‹ˆ๋‹ค.

Acrivon Therapeutics Inc์˜ ์ด์ž์‚ฐ์ด์ต๋ฅ (ROA)์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Acrivon Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์ด์ž์‚ฐ์ด์ต๋ฅ (ROA)์€ -47.75์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 0.76์ž…๋‹ˆ๋‹ค.

Acrivon Therapeutics Inc์˜ ์˜์—…์ด์ต์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Acrivon Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์˜์—…์ด์ต์€ -84.11M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 5.70์ž…๋‹ˆ๋‹ค.
tradingkey.logo
์œ„ํ—˜ ๊ฒฝ๊ณ : ์ €ํฌ ์›น์‚ฌ์ดํŠธ์™€ ๋ชจ๋ฐ”์ผ ์•ฑ์€ ํŠน์ • ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ผ๋ฐ˜์ ์ธ ์ •๋ณด๋งŒ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Finsights๋Š” ์žฌ์ •์  ์กฐ์–ธ์ด๋‚˜ ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ์ •๋ณด ์ œ๊ณต์ด Finsights๊ฐ€ ๊ธˆ์œต ์กฐ์–ธ์ด๋‚˜ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ•ด์„๋˜์–ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค.
ํˆฌ์ž ์ƒํ’ˆ์€ ํˆฌ์ž ์›๊ธˆ ์†์‹ค์„ ํฌํ•จํ•œ ์ƒ๋‹นํ•œ ํˆฌ์ž ์œ„ํ—˜์— ๋…ธ์ถœ๋˜์–ด ์žˆ์œผ๋ฉฐ, ๋ชจ๋“  ์‚ฌ๋žŒ์—๊ฒŒ ์ ํ•ฉํ•˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํˆฌ์ž ์ƒํ’ˆ์˜ ๊ณผ๊ฑฐ ์„ฑ๊ณผ๋Š” ๋ฏธ๋ž˜ ์„ฑ๊ณผ๋ฅผ ๋ณด์žฅํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
Finsights๋Š” ์ œ3์ž ๊ด‘๊ณ ์ฃผ๋‚˜ ์ œํœด์‚ฌ๊ฐ€ ์ €ํฌ ์›น์‚ฌ์ดํŠธ๋‚˜ ๋ชจ๋ฐ”์ผ ์•ฑ ๋˜๋Š” ๊ทธ ์ผ๋ถ€์— ๊ด‘๊ณ ๋ฅผ ๊ฒŒ์žฌํ•˜๊ฑฐ๋‚˜ ์ „๋‹ฌํ•  ์ˆ˜ ์žˆ๋„๋ก ํ—ˆ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์‚ฌ์šฉ์ž๊ฐ€ ๊ด‘๊ณ ์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ฐฉ์‹์— ๋”ฐ๋ผ ์ด๋“ค๋กœ๋ถ€ํ„ฐ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ยฉ ์ €์ž‘๊ถŒ: FINSIGHTS MEDIA PTE. LTD. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ 
์ด์šฉ ์•ฝ๊ด€
๊ฐœ์ธ์ •๋ณด ์ฒ˜๋ฆฌ๋ฐฉ์นจ
์ฟ ํ‚ค ์ •์ฑ